Skip to main content
. 2022 Jun 10;56(5):689–697. doi: 10.1007/s43441-022-00422-z

Table 8.

CDxs targeting PD-L1 protein expression for NSCLC

FDA-approved companion diagnostic FDA-approved therapeutic products
Keytruda® (pembrolizumab) Libtayo® (cemiplimab-rwlc) Tecentriq® (atezolizumab) Opdivo®
(Nivolumab) + Yervoy®
(ipilimumab)
PD-L1 IHC 22C3 pharmDx x x
Ventana PD-L1 (SP142) assay x
PD-L1 IHC 28–8 pharmDX x
VENTANA PD-L1 (SP263) assay x